Literature DB >> 35022128

Narcolepsy-like symptoms triggered by lemborexant in the context of hyperactive delirium in a patient with bipolar depression: a case report.

Shintaro Shibata1, Yasunori Oda1, Nozomi Ohki1, Yuki Ikemizu1, Ryunosuke Hayatsu1, Yuki Hirose1, Masaomi Iyo1.   

Abstract

Lemborexant is a dual orexin antagonist and is considered a safe and effective hypnotic. Dual orexin antagonists induce physiological sleep by blocking orexin receptors. Although the blockade of orexin signaling has triggered narcolepsy-like symptoms in rodents, there is currently no evidence of lemborexant inducing narcolepsy-like symptoms in humans. We describe the case of a 79-year-old Japanese woman with bipolar depression who experienced lemborexant-induced cataplexy and sleep attack. Her previous results on the Multiple Sleep Latency Test excluded the diagnosis of narcolepsy. She experienced narcolepsy-like symptoms on 2 occasions after she was administered lemborexant, in the context of hyperactive delirium, but not in a relaxed state. Her case suggests that lemborexant could trigger narcolepsy-like symptoms in patients with hyperactive delirium, even those with no history of narcolepsy. This case also emphasizes that clinicians must be very careful when they prescribe lemborexant to patients who experience hyperactive delirium. CITATION: Shibata S, Oda Y, Ohki N, et al. Narcolepsy-like symptoms triggered by lemborexant in the context of hyperactive delirium in a patient with bipolar depression: a case report. J Clin Sleep Med. 2022;18(5):1459-1462.
© 2022 American Academy of Sleep Medicine.

Entities:  

Keywords:  DORA; cataplexy; dual orexin receptor antagonist; hyperactive delirium; lemborexant; narcolepsy; orexin; sleep attack

Mesh:

Substances:

Year:  2022        PMID: 35022128      PMCID: PMC9059587          DOI: 10.5664/jcsm.9882

Source DB:  PubMed          Journal:  J Clin Sleep Med        ISSN: 1550-9389            Impact factor:   4.062


  11 in total

1.  Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial.

Authors:  David Michelson; Ellen Snyder; Erin Paradis; Mary Chengan-Liu; Duane B Snavely; Jill Hutzelmann; James K Walsh; Andrew D Krystal; Ruth M Benca; Martin Cohn; Christopher Lines; Thomas Roth; W Joseph Herring
Journal:  Lancet Neurol       Date:  2014-03-27       Impact factor: 44.182

2.  Promotion of sleep by targeting the orexin system in rats, dogs and humans.

Authors:  Catherine Brisbare-Roch; Jasper Dingemanse; Ralf Koberstein; Petra Hoever; Hamed Aissaoui; Susan Flores; Celia Mueller; Oliver Nayler; Joop van Gerven; Sanne L de Haas; Patrick Hess; Changbin Qiu; Stephan Buchmann; Michael Scherz; Thomas Weller; Walter Fischli; Martine Clozel; François Jenck
Journal:  Nat Med       Date:  2007-01-28       Impact factor: 53.440

3.  Lemborexant, A Dual Orexin Receptor Antagonist (DORA) for the Treatment of Insomnia Disorder: Results From a Bayesian, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study.

Authors:  Patricia Murphy; Margaret Moline; David Mayleben; Russell Rosenberg; Gary Zammit; Kate Pinner; Shobha Dhadda; Quan Hong; Luigi Giorgi; Andrew Satlin
Journal:  J Clin Sleep Med       Date:  2017-11-15       Impact factor: 4.062

4.  In Vitro and In Silico Characterization of Lemborexant (E2006), a Novel Dual Orexin Receptor Antagonist.

Authors:  Carsten Theodor Beuckmann; Michiyuki Suzuki; Takashi Ueno; Kazuya Nagaoka; Tohru Arai; Hiroyuki Higashiyama
Journal:  J Pharmacol Exp Ther       Date:  2017-05-30       Impact factor: 4.030

5.  Induction of narcolepsy-like symptoms by orexin receptor antagonists in mice.

Authors:  Mahesh K Kaushik; Kosuke Aritake; Yoan Cherasse; Aya Imanishi; Takashi Kanbayashi; Yoshihiro Urade; Masashi Yanagisawa
Journal:  Sleep       Date:  2021-02-20       Impact factor: 5.849

6.  Long-term effectiveness and safety of lemborexant in adults with insomnia disorder: results from a phase 3 randomized clinical trial.

Authors:  Jane Yardley; Mikko Kärppä; Yuichi Inoue; Kate Pinner; Carlos Perdomo; Kohei Ishikawa; Gleb Filippov; Naoki Kubota; Margaret Moline
Journal:  Sleep Med       Date:  2021-02-01       Impact factor: 3.492

7.  Amygdala lesions reduce cataplexy in orexin knock-out mice.

Authors:  Christian R Burgess; Yo Oishi; Takatoshi Mochizuki; John H Peever; Thomas E Scammell
Journal:  J Neurosci       Date:  2013-06-05       Impact factor: 6.167

8.  Dual orexin receptor antagonists increase sleep and cataplexy in wild type mice.

Authors:  Carrie E Mahoney; Takatoshi Mochizuki; Thomas E Scammell
Journal:  Sleep       Date:  2020-06-15       Impact factor: 5.849

Review 9.  Novel class of medications, orexin receptor antagonists, in the treatment of insomnia - critical appraisal of suvorexant.

Authors:  Jessica L Norman; Sarah L Anderson
Journal:  Nat Sci Sleep       Date:  2016-07-14

10.  Reduced plasma orexin-A levels in patients with bipolar disorder.

Authors:  Shoko Tsuchimine; Kotaro Hattori; Miho Ota; Shinsuke Hidese; Toshiya Teraishi; Daimei Sasayama; Hiroaki Hori; Takamasa Noda; Sumiko Yoshida; Fuyuko Yoshida; Hiroshi Kunugi
Journal:  Neuropsychiatr Dis Treat       Date:  2019-08-06       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.